Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases
- 1 February 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (2) , 249-254
- https://doi.org/10.1023/a:1008354323167
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes?International Journal of Radiation Oncology*Biology*Physics, 2000
- Concomitant brain radiotherapy and vinorelbine–ifosfamide–cisplatin chemotherapy in brain metastases of non-small cell lung cancerLung Cancer, 1999
- Identification of prognostic factors in patients with brain metastases: a review of 1292 patientsInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsPublished by Elsevier ,1997
- The charing cross hospital experience with temozolomide in patients with gliomasEuropean Journal Of Cancer, 1996
- Response of Brain Metastases from Lung Cancer to Systemic Chemotherapy with Carboplatin and EtoposideOncology, 1996
- Surgical treatment of multiple brain metastasesJournal of Neurosurgery, 1993
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990
- Radiation‐induced dementia in patients cured of brain metastasesNeurology, 1989
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989